Jane Street Group, LLC Morphic Holding, Inc. Transaction History

Jane Street Group, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$26.12 - $34.07 $2.23 Million - $2.91 Million	85,314 Added 185.62%	131,276 $4.47 Million
Q1 2024 May 15, 2024	SELL	$26.64 - $40.31 $1.49 Million - $2.25 Million	-55,926 Reduced 54.89%	45,962 $1.62 Million
Q4 2023 Feb 14, 2024	SELL	$19.95 - $31.0 $162,772 - $252,929	-8,159 Reduced 7.41%	101,888 $2.94 Million
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $1.85 Million - $5.14 Million	86,580 Added 368.94%	110,047 $2.52 Million
Q2 2023 Aug 14, 2023	SELL	$34.33 - $62.11 $476,088 - $861,341	-13,868 Reduced 37.14%	23,467 $1.35 Million
Q1 2023 May 15, 2023	BUY	$26.01 - $48.69 $713,194 - $1.34 Million	27,420 Added 276.55%	37,335 $1.41 Million
Q4 2022 Feb 14, 2023	BUY	$24.14 - $30.37 $30,730 - $38,661	1,273 Added 14.73%	9,915 $265,000
Q3 2022 Nov 14, 2022	SELL	$22.23 - $33.37 $36,590 - $54,927	-1,646 Reduced 16.0%	8,642 $245,000
Q3 2022 Nov 14, 2022	SELL	$22.23 - $33.37 $36,590 - $54,927	-1,646 Reduced 16.0%	8,642 $245,000
Q2 2022 Aug 16, 2022	BUY	$19.74 - $43.01 $203,085 - $442,486	10,288 New	10,288 $223,000
Q1 2022 May 17, 2022	SELL	$36.25 - $52.02 $188,028 - $269,827	-5,187 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$43.27 - $65.72 $137,858 - $209,383	-3,186 Reduced 38.05%	5,187 $246,000
Q3 2021 Nov 16, 2021	BUY	$53.61 - $67.5 $448,876 - $565,177	8,373 New	8,373 $474,000
Q2 2021 Aug 16, 2021	SELL	$45.13 - $64.99 $496,384 - $714,825	-10,999 Closed	0 $0
Q1 2021 May 18, 2021	BUY	$29.77 - $84.85 $327,440 - $933,265	10,999 New	10,999 $696,000

4.71M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.